Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matthew Schneiderjan"'
CSIG-34. LIN28B-LET-7-PBK PATHWAY IS AN IMPORTANT REGULATOR OF GROUP 3 MEDULLOBLASTOMA PROLIFERATION
Autor:
Shubin Shahab, Jessica Sun, Haritha Kunhiraman, Matthew Schneiderjan, Kyle Juraschka, Sachin Kumar, Michael Taylor, Tobey MacDonald, Anna Kenney
Publikováno v:
Neuro-Oncology. 24:vii46-vii46
Children with Group 3 medulloblastoma (MB) have a very poor long-term outcome and many do not survive beyond 5 years. Several drivers for Group 3 MB have been identified but none have resulted in targeted therapy to date. LIN28B is a stem cell factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53681554295e2b729f778cc1d558c6ba
https://doi.org/10.1093/neuonc/noac209.183
https://doi.org/10.1093/neuonc/noac209.183
Autor:
Jingbo Liu, Yoon Jae Cho, Hongying Zhang, William C. Petersen, Matthew Schneiderjan, Liangping Yuan, Tobey J. MacDonald
Publikováno v:
Cancer Letters. 354:68-76
Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c50713d32f0ea9a4e2f04812e4f6cb4
https://doi.org/10.1016/j.canlet.2014.07.038
https://doi.org/10.1016/j.canlet.2014.07.038
Autor:
Tobey J. MacDonald, Bryan Philbrook, Claire Mazewski, Dolly Aguilera, Matthew Schneiderjan, Joshua J. Chern, James Felker, Edna Chow-Maneval, Bree R. Eaton
Publikováno v:
Neuro-Oncology. 20:i67-i67
A 2 month old child with a large hemispheric tumor; after subtotal resection, pathology showed pilomyxoid astrocytoma with BRAFV600E mutation by immunohistochemistry and pyrosequencing. He had multiple episodes of radiographic and clinical progressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104b20635aed84584ffab16e41cf951e
https://doi.org/10.1093/neuonc/noy059.179
https://doi.org/10.1093/neuonc/noy059.179